<DOC>
	<DOCNO>NCT01767896</DOCNO>
	<brief_summary>The purpose study compare immunogenicity safety ASP7374 ( cell-culture derive influenza vaccine ) approve egg-derived trivalent inactivate vaccine ( TIV ) elderly subject .</brief_summary>
	<brief_title>Phase-3 Study ASP7374 , Cell-culture-derived Influenza Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Medically stable , judged basis history concurrent disease Subject understand procedure protocol willing comply protocol Scheduled receive another vaccine study Received influenza HA vaccine within 180 day prior screen Received schedule receive live vaccine within 28 day prior vaccination study vaccine , receive schedule receive inactivate vaccine toxoid within 7 day prior vaccination study vaccine Diagnosis immune deficit past , family member ( within third degree kinship ) diagnosis congenital immunodeficiency syndrome Received one follow medication treatment prior vaccination study vaccine : Interferon formulation , drug affect immune system , corticosteroid , GCSF , MCSF , human immunoglobulin product , blood product History anaphylactic shock allergic reaction generalize eruption due food drug ( include vaccine ) allergy , fever ≥39.0°C within 2 day previous vaccination ( influenza vaccine others ) History seizure History GuillainBarre syndrome acute disseminate encephalomyelitis ( ADEM ) Confirmed diagnosis influenza within 84 day prior screen test Body temperature ≥37.5°C Day 1 ( vaccination ) Immunological test reveal positive HBs antigen , HCV antibody , HIV antigen and/or antibody</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Influenza vaccine</keyword>
</DOC>